Highland Capital Management Fund Advisors, L.P. Aerie Pharmaceuticals Inc Transaction History

Highland Capital Management Fund Advisors, L.P.

$846 Million
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $10.1 Million - $24.1 Million	1,584,113 Added 511.37%	1,893,891 $28.7 Million
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $1.32 Million - $1.65 Million	-87,220 Reduced 21.97%	309,778 $4.96 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $600,922 - $957,261	-45,802 Reduced 10.34%	396,998 $7.09 Million
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $748,680 - $1.01 Million	62,390 Added 16.4%	442,800 $6.54 Million
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $5.32 Million - $11.5 Million	-449,200 Reduced 54.15%	380,410 $5.14 Million
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $376,000 - $532,596	21,219 Added 2.62%	829,610 $20.1 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $14.9 Million - $22.6 Million	808,391 New	808,391 $15.5 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account